LGND Q1 2025 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45M+46.3% YoY

Gross Profit

$40M89.3% margin

Operating Income

-$36M-79.9% margin

Net Income

-$42M-93.6% margin

EPS (Diluted)

$-2.21

QoQ Revenue Growth

+5.9%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$905M

Total Liabilities

$110M

Stockholders' Equity

$796M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$31M	+46.3%
Gross Profit	$40M	$20M	+103.3%
Operating Income	-$36M	$3M	-1312.0%
Net Income	-$42M	$86M	-149.3%

Revenue Segments

Royalty

$27M35%

Intangible Royalty Assets

$22M27%

Material Sales, Captisol

$13M17%

Financial Royalty Assets

$6M7%

Kyprolis

$5M6%

Rylaze

$3M4%

Evomela

$2M2%

Teriparatide Injection

$1M1%